The FDA designates the TOBY Test as a breakthrough device, revolutionizing bladder cancer detection with a non-invasive, ...

In a multi-institutional study published in Science Direct, researchers revealed that testing urine-based tumor DNA (utDNA) ...

Invasive bladder cancer can be treated through immunotherapy involving Bacillus Calmette-Guérin (BCG), but some 40%-60% of ...

A mucoadhesive nanoplatform improves bladder cancer imaging by selectively targeting tumors and enhancing visualization for more precise non-invasive diagnosis.

A new cancer detection test to analyze volatile organic compounds through urine analysis, was granted the Breakthrough Device Designation status by the U.S. FDA. The system, which is built on gas ...

BCG therapy—the gold standard treatment for non-muscle invasive bladder cancer (NMIBC), where the cancer has not penetrated ...

Discover the latest updates to the EAU guidelines for muscle-invasive and metastatic bladder cancer in 2025. Learn more.

Bladder cancer, often misunderstood, affects both men and women, not just the elderly. While smoking is a significant risk ...

A new review was published in Volume 16 of Oncotarget on June 17, 2025, titled "Optimizing enfortumab vedotin plus pembrolizumab therapy." ...

Johnson & Johnson has kicked off a marketing application in the US for TAR-200 as a treatment for a form of bladder cancer, using a novel technology that releases the drug intravesically, or ...

AstraZeneca has revealed the data for Imfinzi in muscle-invasive bladder cancer (MIBC) that it hopes will be enough to secure FDA approval – although the jury is out on that.